UK markets open in 6 hours 25 minutes

ERYTECH Pharma S.A. (ERYP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.11-0.26 (-4.08%)
At close: 4:00PM EDT
6.08 -0.03 (-0.49%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.37
Open6.40
Bid5.95 x 2200
Ask6.08 x 1800
Day's range6.00 - 6.50
52-week range4.10 - 13.95
Volume780,447
Avg. volume1,025,107
Market cap172.648M
Beta (5Y monthly)1.87
PE ratio (TTM)N/A
EPS (TTM)-4.01
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.88
  • Globe Newswire

    ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL

    ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL Fast Track designation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today that the U.S. Food and Drug Administration

  • Globe Newswire

    ERYTECH to Participate in the BTIG Virtual Biotechnology Conference

    ERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France), July 27, 2021 –ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9th. BTIG Virtual Biotechnology Conference

  • Globe Newswire

    ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

    ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients Meeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License Application (BLA) for eryaspase for the treatment of ALL patients who developed hypersensitivity reactions to prior asparaginase therapy, supported by the NOPHO1-sponsored Phase 2 trial data, previously presented at the ASH 2020 Annual Meeting The Company expects to submit the BLA before the end of the year Cambridg